Development of intranasal influenza vaccine
نویسندگان
چکیده
منابع مشابه
Intranasal influenza vaccine in a working population.
In the present study, we assessed the incidence of adverse events and influenza-like symptoms in a working population in Switzerland that was vaccinated against influenza. A total of 12,582 individuals of working age (<65 years old) were offered a free influenza vaccine of their choice (injectable or intranasal vaccine) in October and November 2000. Of these individuals, 1600 were vaccinated ag...
متن کاملAcceptability of intranasal live attenuated influenza vaccine, influenza knowledge and vaccine intent in The Gambia
BACKGROUND The burden of influenza is increasingly recognised in Africa. The WHO recommends introducing influenza vaccination to high-risk groups: pregnant women, children <5 years, and the elderly. The Gambia currently has no influenza vaccination policy, but the NASIMMUNE study, a clinical trial of intranasal live attenuated influenza vaccines (LAIV) in young children provided an opportunity ...
متن کاملChallenges and Perspectives toward Development of more Effective Influenza Vaccine
Influenza viruses continue to be a major health threat in human and bird populations. The improvements in formulation and production level of the current influenza vaccines are not sufficient to afford complete protection. The continuous antigenic drifts and emergence of endemic and zoonotic strains make influenza vaccine planning difficult. Concern about the emergence of new influenza pandemic...
متن کاملDevelopment of mucosal adjuvants for intranasal vaccine for H5N1 influenza viruses
An increasing number of infections of highly pathogenic avian influenza virus (H5N1) in humans has been reported in South-East Asia and other areas of the world. High mortality (>60%) of this viral infection and its pathosis of systemic infection are features of this new human disease. Moreover, there is great concern that this avian H5N1 virus could cause a pandemic of new influenza in humans,...
متن کاملAdverse events reported following live, cold-adapted, intranasal influenza vaccine.
CONTEXT In June 2003, the US Food and Drug Administration licensed a trivalent live, attenuated influenza vaccine (LAIV-T) for intranasal administration to healthy persons 5 to 49 years of age. Although prelicensure testing involved 20 228 vaccinees, clinical trials were not of sufficient size to detect rare adverse events reliably. OBJECTIVE To identify adverse events reported following LAIV...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Drug Delivery System
سال: 2010
ISSN: 1881-2732,0913-5006
DOI: 10.2745/dds.25.15